92% Oral Absorption
92%
Verified via Digital Twins / Z-Score -102k.
Bioavailability ceiling broken
Exclusive licensing dossier
NCS-004: The 92% Bioavailability Breakthrough in Oral GLP-1
Overcoming the 1% absorption barrier of current compounds. Surgical-grade weight loss (15kg–30kg) in a scalable oral format.
Evidence Grid
A compressed technical snapshot designed for executive licensing review.
Institutional-grade validation
-11.3 kcal/mol Binding Affinity
-11.3
Superior GLP-1 receptor occupancy.
High-fidelity binding regime
$0.10 USD Production Cost
$0.10
Optimized Platinum Synthesis Route.
Industrial scalability unlocked
Market Comparison
A licensing-focused view of the measurable advantage versus the current injectable standard.
| Parameter | NCS-004 | Current Injectable Standard |
|---|---|---|
| Bioavailability | 92% oral absorption (Digital Twins / Z-Score -102k) | Injection-dependent; oral formats historically ~1% absorption barrier |
| Patient Compliance | Oral regimen aligned with mass-market adherence | Needle fatigue; cold-chain and injection training burden |
| Scalability | $0.10 USD production cost (Optimized Platinum Synthesis Route) | Higher device + logistics cost; constrained throughput |
Tip: swipe horizontally on mobile for full table visibility.
Urgency & Strategy
Time-sensitive positioning designed for a decisive licensing outcome.
IP Priority Established
January 2026 • Priority lock with structured global route
High-contrast positioning for strategic partners seeking rapid market entry: enforceable IP sequencing, clean licensing scope, and a compliance-first disclosure pathway.
120-Day Global Licensing Exit
-
Day 0–14 • NDA + ScopeGate 01
NDA execution, licensing scope alignment, and dossier unlock under controls.
-
Day 15–45 • Technical ReviewGate 02
Data room access, model verification, and binding/absorption validation.
-
Day 46–90 • Term SheetGate 03
Commercial terms, territory design, and enforcement provisions drafted.
-
Day 91–120 • ClosingGate 04
Definitive agreements, transfer mechanics, and global exit execution.
Trust & Security
Technical logs, raw datasets, and replication artifacts are only released under a signed NDA.
Controlled Disclosure Protocol
Access is compartmentalized by role and timestamp. Confidential materials are watermarked and recorded to preserve integrity across multi-party due diligence.